Alpha Cognition: Focused on Neurodegenerative Diseases
Alpha Cognition is a clinical-stage, biopharmaceutical company. Their main focus is to develop treatments for neurodegenerative diseases, like Alzheim …
Dedicated to developing treatments for neurodegenerative diseases
Alpha Cognition is a clinical-stage, biopharmaceutical company. Their main focus is to develop treatments for neurodegenerative diseases, like Alzheimer's, Dementia, and Amyotrophic Lateral Sclerosis (ALS).
About ALPHA-1062
ALPHA-1062 is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. Furthermore, it is a prodrug of an approved AChEl, galantamine.
CEO, Michael McFadden says, "It will be one of the first innovations, if approved, in Alzheimer's in over a decade."
Additionally, ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. Moreover, it is in preclinical development for the treatment of ALS. Not to mention, ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.
For more information on Alpha Cognition (TSX.V: ACOG, OTCQB: ACOGF) please click the investor request info button.
Latest Articles
Hot Companies
You might also like
BTV Showcases Contango Ore, Critical Elements Lithium, Dryden Gold, FireFox Gold, Kirkland Lake, Klondike Gold, and Selkirk Mines
This week, BTV - Business Television we feature growth-focused mining companies advancing major projects across North America and Europe. From emerging producers and strategic combinations to high-grade exploration and critical mineral development, this episode highlights the next wave of opportunity in the resource sector, including:
Selkirk Copper: A Yukon restart positioned to deliver new Canadian copper supply by 2028
A 50,000-metre drill program began last summer to expand understanding of the resource and guide updated mine design. The goal is to define a 12–15 year mine life while refreshing permits and engineering.
